These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28858541)

  • 61. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.
    Panda A; Obmann VC; Lo WC; Margevicius S; Jiang Y; Schluchter M; Patel IJ; Nakamoto D; Badve C; Griswold MA; Jaeger I; Ponsky LE; Gulani V
    Radiology; 2019 Sep; 292(3):685-694. PubMed ID: 31335285
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
    Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
    Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
    Sadoughi N; Krishna S; McInnes MDF; Flood TA; Breau RH; Morash C; Schieda N
    AJR Am J Roentgenol; 2018 Sep; 211(3):W158-W165. PubMed ID: 29995495
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical-imaging metrics for the diagnosis of prostate cancer in PI-RADS 3 lesions.
    Kang Z; Margolis DJ; Tian Y; Li Q; Wang S; Wang L
    Urol Oncol; 2024 Nov; 42(11):371.e1-371.e10. PubMed ID: 38969546
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis.
    Wu M; Krishna S; Thornhill RE; Flood TA; McInnes MDF; Schieda N
    J Magn Reson Imaging; 2019 Sep; 50(3):940-950. PubMed ID: 30701625
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?
    An JY; Harmon SA; Mehralivand S; Czarniecki M; Smith CP; Peretti JA; Wood BJ; Pinto PA; Choyke PL; Shih JH; Turkbey B
    Abdom Radiol (NY); 2018 Dec; 43(12):3436-3444. PubMed ID: 29752491
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.
    Nguyentat M; Ushinsky A; Miranda-Aguirre A; Uchio E; Lall C; Shirkhoda L; Lee T; Green C; Houshyar R
    Curr Probl Diagn Radiol; 2018 Nov; 47(6):404-409. PubMed ID: 29126575
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PI-RADS v2 and ADC values: is there room for improvement?
    Jordan EJ; Fiske C; Zagoria R; Westphalen AC
    Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
    Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
    BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
    Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
    Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.
    Felker ER; Raman SS; Shakeri S; Mirak SA; Bajgiran AM; Kwan L; Khoshnoodi P; ElKhoury FF; Margolis DJA; Karow D; Lu DSK; White N; Marks LS
    AJR Am J Roentgenol; 2019 Aug; 213(2):365-370. PubMed ID: 31039011
    [No Abstract]   [Full Text] [Related]  

  • 75. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
    Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
    BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transrectal ultrasound-guided targeted biopsy of transition zone prostate cancer under cognitive registration with prebiopsy MRI and sonographic findings.
    Won SY; Cho NH; Choi YD; Park SY
    Clin Radiol; 2020 Feb; 75(2):157.e21-157.e27. PubMed ID: 31677880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
    Lim C; Flood TA; Hakim SW; Shabana WM; Quon JS; El-Khodary M; Thornhill RE; El Hallani S; Schieda N
    J Magn Reson Imaging; 2016 Mar; 43(3):726-36. PubMed ID: 26303719
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
    Bajgiran AM; Mirak SA; Sung K; Sisk AE; Reiter RE; Raman SS
    AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
    [No Abstract]   [Full Text] [Related]  

  • 79. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
    Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
    Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
    Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.